JP2010539508A5 - - Google Patents

Download PDF

Info

Publication number
JP2010539508A5
JP2010539508A5 JP2010525420A JP2010525420A JP2010539508A5 JP 2010539508 A5 JP2010539508 A5 JP 2010539508A5 JP 2010525420 A JP2010525420 A JP 2010525420A JP 2010525420 A JP2010525420 A JP 2010525420A JP 2010539508 A5 JP2010539508 A5 JP 2010539508A5
Authority
JP
Japan
Prior art keywords
ccr4
pamphlet
tumor
activity
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010525420A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010539508A (ja
JP5774309B2 (ja
Filing date
Publication date
Priority claimed from GB0718167A external-priority patent/GB0718167D0/en
Application filed filed Critical
Publication of JP2010539508A publication Critical patent/JP2010539508A/ja
Publication of JP2010539508A5 publication Critical patent/JP2010539508A5/ja
Application granted granted Critical
Publication of JP5774309B2 publication Critical patent/JP5774309B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010525420A 2007-09-18 2008-09-18 癌マーカーおよび治療ターゲット Expired - Fee Related JP5774309B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0718167.0 2007-09-18
GB0718167A GB0718167D0 (en) 2007-09-18 2007-09-18 Cancer marker and therapeutic target
PCT/GB2008/003160 WO2009037454A2 (en) 2007-09-18 2008-09-18 Cancer marker and therapeutic target

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015131752A Division JP6234967B2 (ja) 2007-09-18 2015-06-30 癌マーカーおよび治療ターゲット

Publications (3)

Publication Number Publication Date
JP2010539508A JP2010539508A (ja) 2010-12-16
JP2010539508A5 true JP2010539508A5 (https=) 2012-10-04
JP5774309B2 JP5774309B2 (ja) 2015-09-09

Family

ID=38670078

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010525420A Expired - Fee Related JP5774309B2 (ja) 2007-09-18 2008-09-18 癌マーカーおよび治療ターゲット
JP2015131752A Expired - Fee Related JP6234967B2 (ja) 2007-09-18 2015-06-30 癌マーカーおよび治療ターゲット

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015131752A Expired - Fee Related JP6234967B2 (ja) 2007-09-18 2015-06-30 癌マーカーおよび治療ターゲット

Country Status (11)

Country Link
US (2) US9134293B2 (https=)
EP (3) EP2533047B1 (https=)
JP (2) JP5774309B2 (https=)
AU (1) AU2008300413B2 (https=)
CA (1) CA2699702C (https=)
DK (3) DK2535716T3 (https=)
ES (3) ES2588507T3 (https=)
GB (1) GB0718167D0 (https=)
PL (3) PL2176664T3 (https=)
RU (2) RU2529797C2 (https=)
WO (1) WO2009037454A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0623815Y2 (ja) 1988-10-06 1994-06-22 株式会社大金製作所 エア回転継手のシール装置
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
WO2010037042A2 (en) 2008-09-26 2010-04-01 The General Hospital Corporation Methods for detecting and treating cancer
US11029313B2 (en) 2008-09-26 2021-06-08 The General Hospital Corporation Method of treating cervical neoplasia in patients infected with human papilloma virus
GB0909906D0 (en) * 2009-06-09 2009-07-22 Affitech As Antibodies
WO2011157678A1 (en) * 2010-06-14 2011-12-22 Qiagen Gmbh Method for determination of target cells or tissue for extraction of biomolecules from fixed biological samples
GB201021289D0 (en) * 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
US10266599B2 (en) 2010-12-07 2019-04-23 Cancer Research Technology Limited Antibodies which bind to the human CC chemokine receptor 4 and uses thereof
GB201020738D0 (en) 2010-12-07 2011-01-19 Affitech Res As Antibodies
EP2771488B1 (en) 2011-10-24 2018-03-28 SignalChem Lifesciences Corporation Carbonic anhydrase ix-related markers and use thereof
BR112014013138B1 (pt) 2011-12-01 2022-06-28 Chemocentryx, Inc Compostos de anilinas substituídas como antagonistas de ccr(4) e composição farmacêutica compreendendo os mesmos
GB2512857A (en) * 2013-04-09 2014-10-15 Cancer Res Technology Cancer biomarker
EP3065774B1 (en) * 2013-11-06 2021-05-26 Janssen Biotech, Inc. Anti-ccl17 antibodies
SI3148579T1 (sl) 2014-05-28 2021-07-30 Agenus Inc. Proti GITR antitelesa in postopki z njihovo uporabo
WO2016050904A1 (en) * 2014-10-01 2016-04-07 Sphingotec Gmbh Hgh determination for use to guide prevention of a major adverse cardiac event or a cardiovascular disease in a subject
EP3283886B1 (en) * 2015-04-17 2020-01-15 Eisai Inc. Methods for treating lung cancer
US12366508B2 (en) 2015-07-30 2025-07-22 Qiagen Gmbh Method of preparing a frozen biological sample
CN108883173B (zh) 2015-12-02 2022-09-06 阿吉纳斯公司 抗体和其使用方法
CN110603056A (zh) * 2017-05-19 2019-12-20 日本全药工业株式会社 基于ccr4阻断的调节性t细胞浸润抑制方法及犬的肿瘤性疾病的治疗方法
KR102817790B1 (ko) 2018-08-29 2025-06-05 케모센트릭스, 인크. C-c 케모카인 수용체 4(ccr4) 길항제 및 하나 이상의 면역 체크포인트 억제제를 사용한 병용 요법
EP3885452A1 (en) * 2020-03-23 2021-09-29 Koninklijke Philips N.V. Prediction of radiotherapy response for prostate cancer subject based on chemokine genes

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786158A (en) * 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US5342947A (en) * 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
EP0689606A1 (en) * 1993-03-19 1996-01-03 The Johns Hopkins University ANTIBODIES AND ASSAYS FOR DETERMINING MUTATIONS IN THE $i(APC) GENE
GB9501683D0 (en) 1995-01-27 1995-03-15 Glaxo Group Ltd Substances and their uses
US6498015B1 (en) 1995-06-07 2002-12-24 Icos Corporation Methods of identifying agents that modulate the binding between MDC and an MDC receptor
US6488930B1 (en) * 1999-01-15 2002-12-03 Millennium Pharmaceuticals, Inc. Anti-CCR4 antibodies and methods of use therefor
US6245332B1 (en) 1999-01-15 2001-06-12 The Board Of Trustees Of The Leland Stanford Junior University Modulation of systemic memory T cell trafficking
ATE402192T1 (de) 2000-03-03 2008-08-15 Kyowa Hakko Kogyo Kk Anti-ccr4 antikörper und fragmente davon
US20020132836A1 (en) 2000-10-11 2002-09-19 Chemocentryx Inc. Compounds and methods for modulating CCR4 function
AU2002213467A8 (en) 2000-10-11 2009-07-30 Chemocentryx Inc Modulation of ccr4 function
SI1326617T1 (sl) 2000-10-18 2007-02-28 Schering Ag Uporaba 11 beta-(4-acetilfenil)-17 beta-hidroksi-17 alfa-(1,1,2,2,2-pentafluoroetil)estra-4,9-dien-3-ona za pripravo zdravila za zdravljenje raka dojk, raka jajcnikov, endometrijskega raka, mieloma in meningioma
CA2439279A1 (en) * 2001-02-28 2002-09-06 Protein Design Labs, Inc. Chemokine receptors and disease
US7144903B2 (en) 2001-05-23 2006-12-05 Amgen Inc. CCR4 antagonists
WO2003014153A2 (en) 2001-08-10 2003-02-20 Topigen Pharmaceutique Inc. Cellular virus receptors and methods of use.
CA2458627C (en) 2001-08-31 2013-09-10 Kyowa Kirin Co., Ltd. Human cdr-grafted antibody and antibody fragment thereof
AU2003252478A1 (en) 2002-07-10 2004-02-02 Ono Pharmaceutical Co., Ltd. Ccr4 antagonist and medicinal use thereof
WO2004045526A2 (en) 2002-11-15 2004-06-03 Morehouse School Of Medicine Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
JP2007524362A (ja) * 2003-02-14 2007-08-30 サイグレス ディスカバリー, インコーポレイテッド 癌における治療gpcr標的
US7807389B2 (en) * 2003-03-14 2010-10-05 University Of Rochester Methods and compositions related to joint inflammation diseases
SE0301650D0 (sv) 2003-06-04 2003-06-04 Astrazeneca Ab Novel compounds
SE0301653D0 (sv) 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
WO2005023771A1 (ja) 2003-09-05 2005-03-17 Ono Pharmaceutical Co., Ltd. ケモカインレセプターアンタゴニストおよびその医薬用途
EP1688436A4 (en) * 2003-10-08 2009-12-02 Kyowa Hakko Kirin Co Ltd ANTIBODY COMPOSITION THAT IS ABLE TO SPECIFY CCR4 SPECIFICALLY
JPWO2005053741A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 ケモカイン受容体ccr4に対する遺伝子組換え抗体を含む医薬
WO2005082865A1 (ja) 2004-02-27 2005-09-09 Astellas Pharma Inc. 縮合二環性ピリミジン誘導体
JP2007217282A (ja) 2004-03-04 2007-08-30 Astellas Pharma Inc 置換ピリミジン誘導体
WO2005106471A2 (en) * 2004-04-30 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 4 (ccr4)
JP2007269629A (ja) 2004-06-21 2007-10-18 Astellas Pharma Inc キナゾリン誘導体
RU2296328C1 (ru) * 2005-09-21 2007-03-27 Общество с ограниченной ответственностью "ГЕН" Способ определения предрасположенности к онкологическим заболеваниям и диагностический набор для его осуществления
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
DK2135949T3 (da) 2006-02-14 2013-02-04 Noxxon Pharma Ag MCP-1-bindende nukleinsyrer
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target

Similar Documents

Publication Publication Date Title
JP2010539508A5 (https=)
RU2010123921A (ru) Раковый маркер и терапевтическая мишень
Zubair et al. Advanced approaches to breast cancer classification and diagnosis
Huang et al. Shear stress activates ATOH8 via autocrine VEGF promoting glycolysis dependent-survival of colorectal cancer cells in the circulation
JP2012526544A5 (https=)
Tanaka et al. Inhibition of infiltration and angiogenesis by thrombospondin-1 in papillary thyroid carcinoma
JP2012085556A (ja) 乳がんの診断方法
Han et al. Expression of PTEN and mTOR in pancreatic neuroendocrine tumors
JP6983221B2 (ja) 大腸癌の併用検査
JP2009511524A (ja) ケモカイン発現のegfr依存調節ならびに腫瘍とその副作用の治療及び診断に与えるケモカイン発現調節の影響
Hou et al. Detecting ALK-rearrangement of CTC enriched by nanovelcro chip in advanced NSCLC patients
Ikuta et al. The current management of clear cell sarcoma
JP2008514209A5 (https=)
Liu et al. Neuroendocrine differentiation is predictive of poor survival in patients with stage II colorectal cancer
Wang et al. Relationship between RGS5 expression and differentiation and angiogenesis of gastric carcinoma
Sandri et al. Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma
Obata et al. Association between single nucleotide polymorphisms of drug resistance-associated genes and response to chemotherapy in advanced ovarian cancer
JP7369378B2 (ja) 抗がん剤及びがんを治療するための医薬組成物
JP2012085554A (ja) 乳がんのサブタイプの判別方法
JP2012085555A (ja) 乳がん診断用マーカー
He et al. Three-dimensional nanostructured substrates enable dynamic detection of ALK-rearrangement in circulating tumor cells from treatment-naive patients with stage III/IV lung adenocarcinoma
JP6466911B2 (ja) Ccl22及びccl17癌生物マーカー
JP2008535491A5 (https=)
JPWO2007099852A1 (ja) 固形癌のチロシンキナーゼ阻害剤に対する感受性を検査する方法及び検査キット
US20250290155A1 (en) Clinical workflow for treatment of breast cancer